Christopher P Prior

US Patent:

7176278, Feb 13, 2007

Filed:

Mar 4, 2003

Appl. No.:

10/378094

Inventors:

Christopher P. Prior - King of Prussia PA, US

Assignee:

BioRexis Technology, Inc. - Wilmington DE

International Classification:

A61K 38/26
A61K 38/40
C07K 5/00

US Classification:

530308, 530394, 530402, 4241921, 435 697

Abstract:

The present invention discloses fusion proteins comprising transferrin, lactoferrin or melanotransferrin fused to glucagon-like peptide 1 (GLP-1). In one embodiment of the invention, the fusion protein displays increased serum half-life as compared to a GLP-1 peptide in an unfused state. The invention includes a pharmaceutical composition comprising the GLP-1 fusion protein of the invention and a carrier. The fusion protein of the invention can be administered to a subject for treatment of diseases or conditions treatable by GLP-1, including, but not limited to, diabetes, obesity, congestive heart failure and inflammatory bowel syndrome.

US Patent:

7482013, Jan 27, 2009

Filed:

Mar 14, 2005

Appl. No.:

11/078914

Inventors:

David J. Ballance - Berwyn PA, US
Darrell Sleep - West Bridgford, GB
Christopher P. Prior - Rosemont PA, US
Homayoun Sadeghi - Doylestown PA, US
Andrew J. Turner - King of Prussia PA, US

Assignee:

Human Genome Sciences, Inc. - Rockville MD
Delta Biotechnology Limited - Nottingham

International Classification:

A61K 39/00

US Classification:

4241921, 435 71, 435 697, 530350

Abstract:

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention,as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

US Patent:

7507414, Mar 24, 2009

Filed:

Mar 14, 2005

Appl. No.:

11/078663

Inventors:

Craig A. Rosen - Laytonsville MD, US
Homayoun Sadeghi - Doylestown PA, US
Christopher P. Prior - Rosemont PA, US
Andrew J. Turner - Eagleville PA, US

Assignee:

Human Genome Sciences, Inc. - Rockville MD

International Classification:

A61K 39/00

US Classification:

4241921, 514 12, 530350

Abstract:

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

US Patent:

7785599, Aug 31, 2010

Filed:

Oct 30, 2007

Appl. No.:

11/929677

Inventors:

David J. Ballance - Berwyn PA, US
Christopher P. Prior - Rosemont PA, US
Homayoun Sadeghi - Doylestown PA, US
Andrew J. Turner - King of Prussia PA, US

Assignee:

Human Genome Sciences, Inc. - Rockville MD
Novozymes Biopharma DK A/S - Badsvaerd

International Classification:

A61K 39/00

US Classification:

4241921, 424 851, 435 71

Abstract:

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encodings the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the intention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

US Patent:

7867972, Jan 11, 2011

Filed:

Jul 24, 2007

Appl. No.:

11/782030

Inventors:

David James Ballance - Berwyn PA, US
Christopher P. Prior - Rosemont PA, US
Homayoun Sadeghi - Doylestown PA, US
Andrew J. Turner - King of Prussia PA, US

Assignee:

Pharmacia & Upjohn Company, LLC - Kalamazoo MI

International Classification:

A61K 38/00
C12P 17/00

US Classification:

514 11, 530308, 5303911, 5303919

Abstract:

The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight.

US Patent:

8129504, Mar 6, 2012

Filed:

Aug 28, 2003

Appl. No.:

10/515232

Inventors:

Christopher P. Prior - King of Prussia PA, US
Homayoun Sadeghi - King of Prussia PA, US
Andrew Turner - King of Prussia PA, US

Assignee:

Biorexis Technology, Inc. - Wilmington DE

International Classification:

A61K 38/40
A61K 38/00

US Classification:

5303873, 530394, 530530, 424 169

Abstract:

Pharmaceutical compositions containing modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or increased serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, but does exhibit binding to iron and/or the transferrin receptor. Such fusion proteins may be administered orally.

US Patent:

8158579, Apr 17, 2012

Filed:

Nov 30, 2010

Appl. No.:

12/956623

Inventors:

David James Ballance - Berwyn PA, US
Christopher P. Prior - Rosemont PA, US
Homayoun Sadeghi - Doylestown PA, US
Andrew J. Turner - King of Prussia PA, US

Assignee:

BioRexis Pharmaceutical Corporation - King of Prussia PA

International Classification:

A61K 38/00
A61K 38/26
C12P 17/00

US Classification:

514 11, 530308, 530400, 514 68, 514 69, 514 72

Abstract:

The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight.

US Patent:

20030004142, Jan 2, 2003

Filed:

Apr 17, 2002

Appl. No.:

10/124893

Inventors:

Christopher Prior - Rosemont PA, US
Drore Eisen - Cincinnati OH, US
Louis Herlands - Cambridge MA, US

International Classification:

A61K031/60
A61K031/415
A61K031/405
A61K031/192

US Classification:

514/165000, 514/406000, 514/420000, 514/570000

Abstract:

The invention is directed to uses of non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment and prevention of cellular abnormalities of the lung or bronchial pathway.